Book Value per Share: CytoMed Therapeutics Ltd (GDTC)

Public company logo of CytoMed Therapeutics (GDTC)

Diversification of cell programs for tumor combat reduces risks, as confirmed by the book value per share of CytoMed Therapeutics (GDTC), which currently stands at 0.32. Collaboration with clinics advances personalized therapy for the gut and liver. The creation of affordable allogeneic CAR-T products ensures a technological breakthrough. Current indicator dynamics demonstrate the development vector of equity between reporting periods.

CytoMed (GDTC) - Accounting Value per Share from 02/21/2024 to 10/27/2026

Summary analytical data breakdowns for CytoMed Therapeutics Ltd (GDTC)

- price and consensus price forecast:
Stock Quotes CytoMed|GDTC - Analyst Forecast Prices
- market capitalization data:
Market Capitalization CytoMed Therapeutics Limited|GDTC - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share CytoMed Therapeutics|GDTC - Company Net Assets|Market Capitalization to Book Value Ratio w2.cytomed.sg|GDTC - Company Total Assets
- debt and liquidity data:
Debt to Equity CytoMed Therapeutics|GDTC - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital CytoMed|GDTC - Company Total Debt|Debts to Book Capitalization CytoMed Therapeutics Limited
Analysis of all company metrics:w2.cytomed.sg, GDTC
Manufactured product of CytoMed Therapeutics Ltd

Singaporean cell therapy developer CytoMed Therapeutics (GDTC) operates amidst Asia's regulatory fragmentation, making the company's tangible asset base critical to its survival. When analyzing the projected book value per share, an investor assesses the residual value of net assets divided by the number of shares to determine the business's intrinsic value, stripping away market speculation and geopolitical risks.

Competitor analysis for CytoMed Therapeutics

Accounting Value per Share BeiGene Corp ONC|HALO - Book Price of a Share|RVMD (Revolution Medicines) - Book Value per Share|ascentage.com (AAPG) - Accounting Value per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share OS Therapies, Inc.|Book Value per Share RADX (Radiopharm Theranostics Limited)|Accounting Value per Share artivabio.com ARTV|ANL: Accounting Value per Share|VERU - Net Asset Value per Share|Accounting Value per Share Tempest Tx TPST|XLO: Book Price of a Share|Net Assets per Single Share RENB|MURA (Mural Oncology) - Net Asset Value per Share|Net Assets per Single Share KAPA|Accounting Value per Share OnKure|Curis, Inc. - Book Value per Share|Net Asset Value per Share apollomicsinc.com (APLM)|THAR - Book Value per Share|ADVB - Equity per Share|Accounting Value per Share Genprex (GNPX)|Calidi Biotherapeutics (CLDI) - Accounting Value of a Share|SBFM - Accounting Value per Share|Xenetic Biosciences, Inc. (XBIO) - Book Price of a Share|SLRX - Book Value per Share|Accounting Value of a Share purple-biotech.com|American Oncology Network - Book Value per Share|Net Asset Value per Share BGNE (BeiGene Ltd.)|Net Assets per Single Share Checkpoint Therapeutics, Inc|Accounting Value of a Share elevationoncology.com ELEV|iCAD Corp - Book Value per Share|IKNA: Book Value per Share|Net Assets per Single Share Notable Labs (NTBL)|Viracta Therapeutics, Inc. (VIRX) - Share Book Value|Book Value per Share MOR (MorphoSys Corp)|Net Asset Value per Share NAYA Biosciences Corp (NAYA)|Accounting Value per Share AAPGV